As part of the ongoing transformation of its pharmaceutical business, Bayer has made significant investments in R&D to ...

Bayer heralds pipeline progress, blockbuster launches and advanced flagship products in cell-gene therapy: Our Bureau, Bengaluru Wednesday, April 2, 2025, 14:50 Hrs [IST] Bayer Ph ...

The company is expanding its cardiology portfolio with a new treatment for transthyretin amyloid cardiomyopathy in Europe.

Bayer’s pharma sales will “remain stable” through 2026, division chief Stefan Oelrich, said during the ... toughest year for our turnaround,” CEO Bill Anderson said. The reduction is ...